There’s a stretch of most women’s lives that medicine has largely skipped over. You’ve probably felt the gap yourself — a doctor with no good answers, symptoms treated as separate mysteries instead of one connected shift. That’s starting to get formal attention in Washington. Here’s what actually happened, and what the bill under discussion would do.
The Senate’s first hearing devoted to menopause
You don’t often get a clean, official marker for a gap like this. This month, you got one. The hearing was even built around a phrase from its own title — what the committee itself called “the menopause care gap in America.”
On September 16, 2026, the Senate Special Committee on Aging held its first-ever hearing devoted entirely to menopause. The hearing examined a bipartisan bill aimed at closing gaps in research, provider training, and awareness.
The Advancing Menopause Care and Mid-Life Women’s Health Act
The bill discussed is the Advancing Menopause Care and Mid-Life Women’s Health Act, known in Congress as S.4503 and H.R.9090. It’s led by Senators Patty Murray and Lisa Murkowski, with a companion bill in the House — so if you’re looking for it later, either number will get you to the same legislation.
What the bill would do: authorize $275 million over five years for NIH menopause research and fund provider training programs. It would also support public-awareness campaigns and establish menopause “Centers of Excellence.”
A funding comparison raised at the hearing
If you’ve ever wondered whether a gap like this shows up in dollars, the hearing put real numbers behind it. Testimony there cited NIH menopause research funding at about $78 million in fiscal year 2025, compared with $314 million for prostate cancer research that same year.
Those figures came directly from the hearing record. They’re a snapshot of current federal research allocation for one fiscal year, not a judgment about which condition deserves more funding — you can read them either way and still land on the same underlying facts.
Where the bill stands right now
If you’re tracking this bill, here’s where it stands. It has been reintroduced and referred to committee, with bipartisan sponsors in both chambers.
It has not passed the Senate or the House. A hearing is a formal step, but an early one — committee referral means the bill is still working through the process, not close to a floor vote. If you’re used to seeing bills move fast in headlines, this one is proceeding at the slower, procedural pace most legislation actually follows.
Who’s behind the bipartisan push
If you want the full sponsor list, the Senate bill’s sponsors include Senators Murray, Murkowski, Baldwin, Collins, Klobuchar, and Capito, among other women senators.
That cross-party list is notable on its own. It’s a sign the bill’s provisions drew support from senators who don’t often co-sponsor legislation together — useful context if you’re trying to gauge how this bill compares to others working through Congress right now.
If you try one thing, bookmark the Senate Aging Committee’s hearing page and check back after committee action. That’s the next real signal of whether this bill moves toward a vote, rather than relying on secondhand summaries of where things stand.
This article was produced with the assistance of AI and reviewed by Womens Overview editors prior to publication.